NCT04242407Unknown2 期
A Double-Blind, Placebo-Controlled Evaluation of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 164
- 试验地点
- 4
- 主要终点
- Time-interval weighted summed pain intensity (SPI) with activity
研究概览
简要总结
The primary objective of this study is to evaluate the analgesic efficacy of Dexmedetomidine Transdermal System (DMTS), compared with placebo, in participants following abdominoplasty.
详细描述
This is a randomized, double-blind, placebo-controlled, one-time application study of DMTS or matching placebo over a 4-day treatment period.
Eligible subjects will be randomized in 1:1 ratio to receive DMTS or matching placebo. Subjects will reside at the clinical study unit for up to a total of 7 days. The surgical procedure, the intraoperative anesthesia, and the medication used for infiltration of the wound for local anesthesia before the last stitch will be standardized. During the postoperative period in the clinical study unit, recovery procedures will be standardized.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
The sponsor, the investigator, personnel at the clinical study unit who are directly involved with monitoring and/or performing study procedures and assessments, and the subjects will be blinded to treatment assignment.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily provide written informed consent.
- •Male or female, ≥ 18 years of age.
- •Scheduled to undergo a full abdominoplasty (including repair of small incidental abdominal hernias but not including liposuction).
- •Have a physical status classification of 1 or 2 per the American Society of Anesthesiology.
- •Female subjects are eligible only if all the following apply:
- •Not pregnant, not lactating, and not planning to become pregnant during the study or for 1 menstrual cycle thereafter
- •Surgically sterile; or at least 2 years postmenopausal; or have a monogamous partner who is surgically sterile; or have a same gender sex partner; or is using double-barrier contraception; or practicing abstinence; or using an insertable, injectable, transdermal, or combination oral contraceptive for 3 months prior to the study, during the study, and for 1 month following the study
- •Male subjects with female sex partners of childbearing potential must be surgically sterile or commit to use a reliable method of birth control during the study and for 1 month following the study.
- •Have a body weight > 58 kg and a BMI of 20 to 38 kg/m2, inclusive.
- •Able to understand the study procedures, comply with all study procedures, and agree to participate in the study program for its full duration.
排除标准
- •Known sensitivity to dexmedetomidine or any excipient in the DMTS/placebo or to any peri- or postoperative medication whose use is required in this study.
- •Skin abnormality (eg, scar, tattoo) or unhealthy skin condition (eg, burns, wounds) at the DMTS/matching placebo system application site, according to examination by the investigator at screening or admission to the clinic prior to surgery.
- •Clinically significant abnormal clinical laboratory test value.
- •History of deep vein thrombosis or factor V Leiden deficiency.
- •History of or positive test results for the human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
- •History or clinical manifestations of: a significant renal, hepatic, cardiovascular, metabolic, neurologic, or psychiatric condition; congestive heart failure, peptic ulcer, gastrointestinal bleeding, or other condition that may preclude participation in the study.
- •History of physician-diagnosed migraine, frequent non-vascular headaches (> 5 per month), seizures, or are currently taking anticonvulsants.
- •Have another painful physical condition that may confound the assessments of postoperative pain.
- •History of syncope or other syncopal attacks.
- •Present and/or significant history of postural hypotension (determined through examination by the investigator or designee), or history of severe dizziness or fainting on standing in the opinion of the investigator.
- •Evidence of a clinically significant 12-lead ECG abnormality.
- •Supine heart rate < 60 or > 100 bpm, systolic blood pressure (BP) < 90 or > 140 mmHg, or diastolic BP < 60 or > 90 mmHg, when measured in triplicate: after being supine for at least 5 minutes; after sitting for at least 2 minutes; and after standing for at least 2 minutes.
- •History of alcohol abuse or prescription/illicit drug abuse within the previous 5 years.
- •Positive results on the urine drug screen or alcohol breath test indicative of drugs of abuse or alcohol use at screening and/or clinic check-in.
- •Receiving or have received opioid therapy chronically for > 2 weeks within the month prior to dosing of the study drug.
- •Receiving concurrent therapy that can interfere with the evaluation of efficacy or safety, such as any drug that in the investigator's opinion may exert significant analgesic properties or act synergistically with dexmedetomidine.
- •Used of any natural health products (including chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian, and excluding vitamins or mineral supplements) within 14 days prior to study drug administration and throughout the study, unless in the opinion of the investigator or designee, the product will not interfere with the study procedures or data integrity, or compromise the safety of the subject.
- •Had symptoms of an upper respiratory tract infection within 14 days prior to dosing of the study drug.
- •Utilized oral or injectable corticosteroids within 14 days prior to dosing of the study drug (intranasal and topical corticosteroid use during this time period is allowed).
- •Received any investigational product within 30 days prior to dosing of the study drug.
- •Received DMTS in a previous clinical trial.
- •Sensitivity to opioids, nonsteroidal anti-inflammatory drugs, or antibiotics.
- •In the opinion of the investigator or designee, is considered unsuitable for study entry and/or is unlikely to comply with the study protocol for any reason.
研究组 & 干预措施
DMTS
Active Comparator
DMTS applied to the upper arm
干预措施: DMTS (Drug)
Placebo
Placebo Comparator
Placebo system (with no drug) to match DMTS applied to the upper arm
干预措施: Placebo (Drug)
结局指标
主要结局
Time-interval weighted summed pain intensity (SPI) with activity
时间窗: 4 to 96 hours following surgery
The SPI measured using the 11-point (0 to 10) numeric rating scale, where 0 is equal to no pain and 10 is equal to worst pain, with activity (ie, splinted cough with pillow).
次要结局
- Rescue Medication(4 to 96 hours following surgery)
- Rescue Medication time(4 to 96 hours following surgery)
- Rescue Medication units(4 to 96 hours following surgery)
- Time-interval weighted summed pain intensity (SPI) (rest and activity)(4 to 96 hours following surgery)
- Integrated Pain score and Rescue Medication(4 to 96 hours following surgery)
研究者
研究点 (4)
Loading locations...
相似试验
撤回
4 期
Dexmedetomidine vs Placebo for Pediatric Cleft Palate RepairCleft PalateNCT02915042Baylor College of Medicine
已完成
3 期
A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)AnesthesiaSurgical Procedures, ElectiveNCT00398827Hospira, now a wholly owned subsidiary of Pfizer326
已完成
2 期
The Effect of Dexmedetomidine on Brachial Plexus Block for Shoulder SurgeryNerve PainShoulder PainNCT02225054Women's College Hospital99
已完成
3 期
A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic IntubationAwake Fiberoptic IntubationNCT00383890Hospira, now a wholly owned subsidiary of Pfizer124
已完成
4 期
Spinal or Intravenous Dexmedetomidine in Ambulatory SurgerySurgery AmbulatoryNCT02282319University Hospital, Antwerp150